Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole treatment-withdrawal study in infants with GERD
2006-005212-27Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Eligibility for randomization based on predefined symptom improvement and Efficacy for reducing esophageal and supraesophageal signs and symptoms of infantile GERD. Started Jan 2007; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2006-005212-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005212-27.